Serarslan G., Makbule Kaya Ö., Dirican E. Scale and pustule on dermoscopy of rosacea: a diagnostic clue for demodex species // Dermatol. Pract. Concept. 2021. Vol. 11. N. 1. Article ID e2021139. DOI: https://doi.org/10.5826/dpc.1101a139. PMID: 33614217; PMCID: PMC7875658.
Shi H., Zhang E., Zhang M., Lin T. Narrow-band intense pulsed light as treatment for erythematotelangiectatic rosacea: a retrospective study // J. Drugs Dermatol. 2023. Vol. 22. N. 11. P. 1095–1098. DOI: https://doi.org/10.36849/JDD.4920. PMID: 37943269.
Siddiqui K., Stein Gold L., Gill J. The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis // Springerplus. 2016. Vol. 5. N 1. P. 1151. DOI: https://doi.org/10.1186/s40064-016-2819-8. PMID: 27504249; PMCID: PMC4956638.
Simental-Lara F., Ponce-Olivera R.M. Rosácea fulminante asociada con colitis ulcerativa. Caso clinico // Dermatol. Rev. Mex. 2014. Vol. 58. P. 471–475.
Smith K.W. Perioral dermatitis with histopathologic features of granulomatous rosacea: successful treatment with isotretinoin // Cutis. 1990. Vol. 46. N. 5. P. 413–415. PMID: 2148143.
Smith L.A., Meehan S.A., Cohen D.E. Rosacea fulminans with extrafacial lesions in an elderly man: successful treatment with subantimicrobial-dose doxycycline // J. Drugs Dermatol. 2014. Vol. 13. N. 6. P. 763–765. PMID: 24918570.
Smith M., Wolffsohn J.S., Chiang J.C.B. Topical ivermectin 1.0% cream in the treatment of ocular demodicosis // Cont. Lens. Anterior Eye. 2024. Vol. 47. N. 1. Article ID 102099. DOI: https://doi.org/10.1016/j.clae.2023.102099. Epub 2023 Dec 3. PMID: 38049351.
Snapp R.H. Lewandowsky’s rosacea-like eruption; a clinical study // J. Invest. Dermatol. 1949. Vol. 13. N. 4. P. 175–190. DOI: https://doi.org/10.1038/jid.1949.86. PMID: 15391319.
Sobolewska B., Doycheva D., Deuter C.M. et al. Efficacy of topical ivermectin for the treatment of cutaneous and ocular rosacea // Ocul. Immunol. Inflamm. 2021. Vol. 29. N. 6. P. 1137–1141. DOI: https://doi.org/10.1080/09273948.2020.1727531. Epub 2020 Apr 7. PMID: 32255398.
Stein Gold L., Kircik L., Fowler J. et al.; Ivermectin Phase 3 Study Group. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials // J. Drugs Dermatol. 2014. Vol. 13. N. 11. P. 1380–1386. PMID: 25607706.
Stein L., Kircik L., Fowler J. et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies // J. Drugs Dermatol. 2014. Vol. 13. N. 3. P. 316–323.
Taieb A., Ortonne J.P., Ruzicka T. et al.; Ivermectin Phase III Study Group. Superiority of ivermectin 1% cream over metronidazole 0·75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial // Br. J. Dermatol. 2015. Vol. 172. N. 4. P. 1103–1110. DOI: https://doi.org/10.1111/bjd.13408. Epub 2015 Feb 11. PMID: 25228137.
Tan J., Almeida L.M., Bewley A. et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel // Br. J. Dermatol. 2017. Vol. 176. N. 2. P. 431–438. DOI: https://doi.org/10.1111/bjd.15122. Epub 2017 Jan 23. PMID: 27718519.
Tan J., Schöfer H., Araviiskaia E. et al.; RISE Study Group. Prevalence of rosacea in the general population of Germany and Russia — the RISE study // J. Eur. Acad. Dermatol. Venereol. 2016. Vol. 30. N. 3. P. 428–434. DOI: https://doi.org/10.1111/jdv.13556. PMID: 26915718; PMCID: PMC5067643.
Tan J., Steinhoff M., Berg M. et al.; Rosacea International Study Group. Shortcomings in rosacea diagnosis and classification // Br. J. Dermatol. 2017. Vol. 176. N. 1. P. 197–199. DOI: https://doi.org/10.1111/bjd.14819. PMID: 28098383.
Thibaut de Ménonville S., Rosignoli C., Soares E. et al. Topical treatment of rosacea with ivermectin inhibits gene expression of cathelicidin innate immune mediators, LL-37 and KLK5, in reconstructed and ex vivo skin models // Dermatol. Ther. (Heidelb.). 2017. Vol. 7. N. 2. P. 213–225. DOI: https://doi.org/10.1007/s13555-017-0176-3. Epub 2017 Feb 27. PMID: 28243927; PMCID: PMC5453918.
Thiboutot D., Anderson R., Cook-Bolden F. et al. Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee // J. Am. Acad. Dermatol. 2020. Vol. 82. N. 6. P. 1501–1510. DOI: https://doi.org/10.1016/j.jaad.2020.01.077. Epub 2020 Feb 7. PMID: 32035944.
Two A.M., Wu W., Gallo R.L., Hata T.R. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors // J. Am. Acad. Dermatol. 2015. Vol. 72. N. 5. P. 749–758. DOI: https://doi.org/10.1016/j.jaad.2014.08.028. PMID: 25890455.
US Food and Drug Administration. Mirvaso (brimonidine) gel, 0.33%, for topical use: prescribing information. 2013. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204708lbl.pdf (дата обращения: 16.08.2023).
URL: https://eyewiki.org/Morbihan_Disease
Van Zuuren E.J., Arents B.W.M., van der Linden M.M.D. et al. Rosacea: new concepts in classification and treatment // Am. J. Clin. Dermatol. 2021. Vol. 22. N. 4. P. 457–465. DOI: https://doi.org/10.1007/s40257-021-00595-7. Epub 2021 Mar 23. PMID: 33759078; PMCID: PMC8200341.
Van Zuuren E.J., Fedorowicz Z., Tan J. et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments // Br. J. Dermatol. 2019. Vol. 181. N. 1. P. 65–79. DOI: https://doi.org/10.1111/bjd.17590. Epub 2019 Mar 10. PMID: 30585305; PMCID: PMC6850438.